Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanja Sikirica

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
BMC Psychiatry|January 18, 2016
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHDJean Lachaine, Vanja Sikirica, Karine Mathurin
Neurology and Therapy|April 30, 2017
Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort StudyVanja Sikirica, Per A Gustafsson, Charles Makin
Orphanet Journal of Rare Diseases|March 13, 2024
A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseasesShailja Vaghela, Kaniz Afroz Tanni, Geetanjoli Banerjee, et al.
Patient Preference and Adherence|April 13, 2016
Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetineAlain Joseph, Martin Cloutier, Annie Guérin, et al.
American Journal of Obstetrics and Gynecology|July 7, 2009
Adhesion development and morbidity after repeat cesarean deliveryTogas Tulandi, Mohammed Agdi, Afsoon Zarei, et al.
Journal of Comparative Effectiveness Research|January 26, 2017
The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorderJuliana Meyers, Kavita Gajria, Sean D Candrilli, et al.
Drugs in R&D|November 26, 2013
Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorderVanja Sikirica, Moshe Fridman, Amanda Bruno, et al.
Health Economics|September 14, 2016
Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity DisorderJason Shafrin, Anshu Shrestha, Amitabh Chandra, et al.
Neuropsychiatric Disease and Treatment|April 15, 2017
Access to diagnosis, treatment, and supportive services among pharmacotherapy-treated children/adolescents with ADHD in Europe: data from the Caregiver Perspective on Pediatric ADHD surveyMoshe Fridman, Tobias Banaschewski, Vanja Sikirica, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 7, 2016
Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in GermanyPeter Greven, Vanja Sikirica, Yaozhu J Chen, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
BMC Psychiatry|January 18, 2016
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHDJean Lachaine, Vanja Sikirica, Karine Mathurin
Neurology and Therapy|April 30, 2017
Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort StudyVanja Sikirica, Per A Gustafsson, Charles Makin
Orphanet Journal of Rare Diseases|March 13, 2024
A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseasesShailja Vaghela, Kaniz Afroz Tanni, Geetanjoli Banerjee, et al.
Patient Preference and Adherence|April 13, 2016
Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetineAlain Joseph, Martin Cloutier, Annie Guérin, et al.
American Journal of Obstetrics and Gynecology|July 7, 2009
Adhesion development and morbidity after repeat cesarean deliveryTogas Tulandi, Mohammed Agdi, Afsoon Zarei, et al.
Journal of Comparative Effectiveness Research|January 26, 2017
The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorderJuliana Meyers, Kavita Gajria, Sean D Candrilli, et al.
Drugs in R&D|November 26, 2013
Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorderVanja Sikirica, Moshe Fridman, Amanda Bruno, et al.
Health Economics|September 14, 2016
Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity DisorderJason Shafrin, Anshu Shrestha, Amitabh Chandra, et al.
Neuropsychiatric Disease and Treatment|April 15, 2017
Access to diagnosis, treatment, and supportive services among pharmacotherapy-treated children/adolescents with ADHD in Europe: data from the Caregiver Perspective on Pediatric ADHD surveyMoshe Fridman, Tobias Banaschewski, Vanja Sikirica, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 7, 2016
Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in GermanyPeter Greven, Vanja Sikirica, Yaozhu J Chen, et al.
Pageof 10